iShares Biotechnology ETF (NASDAQ:IBB – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Thursday. The stock traded as high as $219.00 and last traded at $218.0610, with a volume of 9,320 shares traded. The stock had previously closed at $216.35.
iShares Biotechnology ETF Trading Down 0.1%
The stock has a 50-day moving average price of $208.43 and a 200 day moving average price of $184.81.
iShares Biotechnology ETF Cuts Dividend
The firm also recently announced a quarterly dividend, which was paid on Friday, September 18th. Investors of record on Tuesday, September 15th were paid a dividend of $0.0112 per share. This represents a $0.04 dividend on an annualized basis and a yield of 0.0%. The ex-dividend date of this dividend was Tuesday, September 15th. This is a negative change from iShares Biotechnology ETF’s previous quarterly dividend of $0.0238.
Institutional Trading of iShares Biotechnology ETF
Hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE raised its holdings in shares of iShares Biotechnology ETF by 10.8% in the 1st quarter. Bank of America Corp DE now owns 7,259,501 shares of the financial services provider’s stock valued at $1,225,767,000 after purchasing an additional 707,343 shares during the period. Royal Bank of Canada grew its holdings in iShares Biotechnology ETF by 1.0% during the first quarter. Royal Bank of Canada now owns 737,128 shares of the financial services provider’s stock worth $124,464,000 after purchasing an additional 7,434 shares during the period. Albion Financial Group UT grew its holdings in iShares Biotechnology ETF by 1.0% during the third quarter. Albion Financial Group UT now owns 120,782 shares of the financial services provider’s stock worth $25,428,000 after purchasing an additional 1,147 shares during the period. Cetera Investment Advisers grew its holdings in iShares Biotechnology ETF by 9.4% during the first quarter. Cetera Investment Advisers now owns 128,530 shares of the financial services provider’s stock worth $21,702,000 after purchasing an additional 10,994 shares during the period. Finally, Henshaw Capital LLC acquired a new position in iShares Biotechnology ETF during the first quarter worth approximately $20,262,000. 62.45% of the stock is currently owned by institutional investors and hedge funds.
About iShares Biotechnology ETF
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Featured Articles
- Five stocks we like better than iShares Biotechnology ETF
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
